Skip to content
Screener

Intellia Therapeutics NTLA Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$13.8MBeat by $1.6M
EPS-$0.92Beat by $0.10
Revenue estimate$12.2M
EPS estimate-$1.02

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$9.7M
EPS estimate-$0.82

Financials

Q3 2025

Income statement

See full
Revenue$13.8M+51.3%
Operating income-$111.5M+23.0%
Net income-$101.3M+25.3%
EPS (diluted)-$0.92+31.3%

Balance sheet

See full
Cash & equivalents$193.4M+60.5%
Total debt$98.0M-3.6%
Total equity$748.4M-22.3%
Total assets$925.3M-21.1%

Cash flow

See full
Operating cash flow-$76.9M+9.4%
CapEx$29.0K-97.7%
Free cash flow-$76.9M+10.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.85B-7.0%
Enterprise value$1.76B-10.9%
P/S32.2×-12.1×

Profitability

See full
Operating margin-832.2%-194pp
Net margin-774.9%-193pp
FCF margin-717.3%-71.6pp

Returns & leverage

See full
Return on equity-52.1%-0.1pp
Debt / equity0.1×0.0×
Current ratio6.2×-0.5×

FAQ

When did Intellia Therapeutics report Q3 2025 earnings?
Intellia Therapeutics (NTLA) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Intellia Therapeutics's Q3 2025 revenue and EPS?
Intellia Therapeutics reported revenue of $13.8M and eps of $-0.92 for Q3 2025.
Did Intellia Therapeutics beat estimates in Q3 2025?
Revenue beat the consensus estimate of $12.2M by $1.6M. EPS beat the consensus estimate of $-1.02 by $0.10.
How did Intellia Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 51.3% from $9.1M a year earlier and eps grew 31.3% from $-1.34.
Where can I find Intellia Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269479) and the 10-Q periodic report (0001193125-25-269680) directly on SEC EDGAR. The filing index links above go to sec.gov.